1160294-26-7

Basic information

• Product Name: (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate
• Synonyms: (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate;BIBF1120 7.4G;1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-4-[methyl[2-(4- methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester;2,3-Dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-1H-indole-6-carboxylic acid methyl ester;Vargatef Methyl ester;methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate
• CAS NO: 1160294-26-7
• Molecular Formula: C₃₁H₃₃N₅O₄
• Molecular Weight: 539.62482
• Mol File: 1160294-26-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 742.199 °C at 760 mmHg
• Flash Point: 402.667 °C
• Appearance: /
• Density: 1.284
• CAS DataBase Reference: (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate(1160294-26-7)
• EPA Substance Registry System: (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate(1160294-26-7)

Safety Data

• Hazardous Substances Data: 1160294-26-7(Hazardous Substances Data)

Usage

General Description

(Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate is a complex chemical compound with a lengthy and intricate molecular structure. It contains various functional groups including ester, amide, and amine functionalities, and it is characterized by its indoline and phenyl rings. This chemical is of interest due to its potential pharmaceutical applications, particularly in the field of drug development. Its precise properties and potential uses would need to be further investigated through extensive study and analysis.

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 262368-30-9 N-[(4-methyl-piperazin-1-yl)methylcarbonyl]-N-methyl-p-phenylendiamine 
• 109-01-3 1-methyl-piperazine 
• 2653-16-9 2-chloro-N-methyl-N-(4-nitrophenyl)acetamide 
• 1160293-22-0 3-[methoxy(phenyl)methylene]-2-oxoindoline-6-carboxylic acid methyl ester 
• 1663-61-2 triethoxymethylbenzene 
• 14192-26-8 2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester 
• 1139453-98-7 N-methyl-2-(4-methylpiperazin-1-yl)-N-(4-nitrophenyl)-acetamide 
• 1175365-43-1 methyl 1-acetyl-3-[ethoxy(phenyl)methylidene]-2-oxo-2,3-dihydro-7H-indole-6-carboxylate 

Relevant articles and documents

Synthesis of the Kinase Inhibitors Nintedanib, Hesperadin, and Their Analogues Using the Eschenmoser Coupling Reaction

A novel synthetic approach involving an Eschenmoser coupling reaction of substituted 3-bromooxindoles (H, 6-Cl, 6-COOMe, 5-NO2) with two substituted thiobenzanilides in dimethylformamide or acetonitrile was used for the synthesis of eight kinase inhibitor

METHODS FOR PREPARING NINTEDANIB AND INTERMEDIATES THEREOF

The present application provides a method for preparing nintedanib. The method of the present application is carried out by using 4-halo-3-nitro-benzoic acid methyl ester (compound II) and 3-oxo-3-phenylpropionate (compound III) as raw materials, and prep

Preparation method of nintedanib key intermediate

The invention belongs to the technical field of pharmaceutical chemicals, and particularly relates to a preparation method of a nintedanib key intermediate compound II. A compound IV is reduced by adopting a common reaction reagent under the conditions of normal temperature and normal pressure, so that a high-purity compound II can be conveniently obtained. The adopted reaction conditions are mild, high-pressure equipment is avoided, the technical operation is simple, the conditions are mild, the process is safer and more environmentally friendly, and the feasibility of large-scale productionof nintedanib is greatly improved.